Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.58 |
| ▸ | POLA1 | P09884 | 3/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine Triphosphate SCHEMBL15160598 | 0.92 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Gemcitabine Triphosphate SCHEMBL21465271 | 0.92 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Gemcitabine Triphosphate SCHEMBL5598638 | 0.92 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Gemcitabine Triphosphate SCHEMBL3468704 | 0.92 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4PDE4D | |
| SCHEMBL843975 | 0.90 | POLA1 (0.64) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL15038016 | 0.90 | POLA1 (0.59) | POLGPOLA1P2RY2P2RY4PDE4D | |
| SCHEMBL16640138 | 0.90 | POLG (0.60) | POLGPOLA1P2RY2P2RY4PDE4D | |
| SCHEMBL16777764 | 0.90 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL21233069 | 0.90 | POLA1 (0.59) | POLGPOLA1P2RY2P2RY4PDE4D | |
| Psi-6130-Tp SCHEMBL12799368 | 0.90 | POLA1 (0.59) | POLGPOLA1P2RY2P2RY4PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2025061911-A1 | METHODS OF PRODUCING NUCLEOTIDE TRIPHOSPHATES (NTPS) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-27 | — | — | WO | disclosed |
| US-20250074962-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2025-03-06 | — | — | US | disclosed |
| US-20250018062-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNA TX INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240409597-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-12-12 | — | — | US | disclosed |
| US-20240327476-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2024-10-03 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220273555-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2022-09-01 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6849610-B1 | Polynucleotide ligands as anti-viral agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-01 | — | — | US | disclosed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2001038341-A1 | POLYNUCLEOTIDE LIGANDS AS ANTI-VIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409597-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | POLG 114/4885POLA1 52/4885P2RY2 2202/4885 |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | PHAX, NSUN2, RNMT | POLG 510/4885POLA1 350/4885P2RY2 2188/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | POLG 274/4885POLA1 560/4885P2RY2 552/4885 |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | POLG 967/4885POLA1 1123/4885P2RY2 1820/4885 |
| US-20250018062-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLN, POLM | POLG 37/4885POLA1 16/4885P2RY2 2758/4885 |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | PHAX, NSUN2, RNMT | POLG 510/4885POLA1 350/4885P2RY2 2188/4885 |
| US-20250074962-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | NSUN2, RNMT, NSUN3 | POLG 277/4885POLA1 214/4885P2RY2 1684/4885 |
| US-20220273555-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | POLRMT, POLN, MSH2 | POLG 59/4885POLA1 25/4885P2RY2 1489/4885 |
| US-20240327476-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | POLG 71/4885POLA1 22/4885P2RY2 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.